(VIANEWS) – MONTEA (MONT.BR), CTP (CTPNV.AS), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. MONTEA (MONT.BR)
25.8% sales growth and 6.28% return on equity
Montea NV is a public regulated real estate company under Belgian law (GVV/SIR) that specialises in logistical property in Belgium, the Netherlands, France, and Germany. The company is a benchmark player in this market. Montea literally offers its customers the space they need to grow through versatile and innovative property solutions. In this way, Montea creates value for its shareholders. As of 30/06/2023 the property portfolio represented a total surface of 1,921,172 m² spread across 94 locations. Montea NV has been listed on Euronext Brussels (MONT) and Euronext Paris (MONTP) since the end of 2006.
Earnings Per Share
As for profitability, MONTEA has a trailing twelve months EPS of €4.22.
PE Ratio
MONTEA has a trailing twelve months price to earnings ratio of 15.81. Meaning, the purchaser of the share is investing €15.81 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.28%.
Yearly Top and Bottom Value
MONTEA’s stock is valued at €66.70 at 22:20 EST, way below its 52-week high of €80.30 and higher than its 52-week low of €62.20.
More news about MONTEA.
2. CTP (CTPNV.AS)
20.8% sales growth and 14.49% return on equity
CTP N.V. owns, develops, manages, and leases logistics and industrial real estate properties in Central, Western, and Eastern Europe. The company offers various building for small and growing businesses, global enterprises, built to suit, and other offices. It also develops urban parks which are harbour mixed-use building and space types, such as premium offices, retail stores, office services, public spaces, and other amenities. CTP N.V. was founded in 1998 and is based in Amsterdam, the Netherlands. CTP N.V. is a subsidiary of CTP Holding B.V.
Earnings Per Share
As for profitability, CTP has a trailing twelve months EPS of €1.73.
PE Ratio
CTP has a trailing twelve months price to earnings ratio of 7.83. Meaning, the purchaser of the share is investing €7.83 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.49%.
Moving Average
CTP’s value is higher than its 50-day moving average of €12.63 and above its 200-day moving average of €12.32.
Yearly Top and Bottom Value
CTP’s stock is valued at €13.54 at 22:20 EST, below its 52-week high of €14.50 and way above its 52-week low of €9.25.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.4%, now sitting on 630.91M for the twelve trailing months.
More news about CTP.
3. NAVAMEDIC (NAVA.OL)
17.3% sales growth and 10.19% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.2.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 32.58. Meaning, the purchaser of the share is investing kr32.58 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.19%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.3%, now sitting on 454.46M for the twelve trailing months.
More news about NAVAMEDIC.
4. ABN AMRO BANK N.V. (ABN.AS)
17.2% sales growth and 10.93% return on equity
ABN AMRO Bank N.V. provides various banking products and services to retail, private, and business clients in the Netherlands and internationally. It operates through three segments: Personal & Business Banking, Wealth Management, and Corporate Banking. The company provides savings and deposits products; labelled residential mortgage products under the Florius brands; and consumer loans under the Alpha Credit Nederland, Credivance, Defam, Moneyou, and ABN AMRO brands. It also issues, promotes, manages, and processes credit cards; provides revolving credit card facilities and pension schemes, as well as consumer credit and mortgages; and life and non-life insurance products. In addition, it offers asset-based solutions, including working capital solutions, equipment leases and loans, and vendor lease services; private banking and wealth-management-related services; and derivatives and equity clearing services. ABN AMRO Bank N.V. was incorporated in 2009 and is headquartered in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, ABN AMRO BANK N.V. has a trailing twelve months EPS of €2.68.
PE Ratio
ABN AMRO BANK N.V. has a trailing twelve months price to earnings ratio of 4.88. Meaning, the purchaser of the share is investing €4.88 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.93%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 25% and positive 45.9% for the next.
Volume
Today’s last reported volume for ABN AMRO BANK N.V. is 1146690 which is 61.65% below its average volume of 2990680.
Moving Average
ABN AMRO BANK N.V.’s value is below its 50-day moving average of €14.22 and below its 200-day moving average of €14.51.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.1%, now sitting on 8.41B for the twelve trailing months.
More news about ABN AMRO BANK N.V..
